22918-01-0

Basic information

• Product Name: 2-Bromo-4-chloropyridine
• Synonyms: 2-BROMO-4-CHLOROPYRIDINE;4-CHLORO-2-BROMOPYRIDINE;Pyridine, 2-bromo-4-chloro-;2-broMo-4-pyridyl chloride;2-broMo -4-chlorine pyridine;2-Bromo-4-chloropyridine 95%
• CAS NO: 22918-01-0
• Molecular Formula: C₅H₃BrClN
• Molecular Weight: 192.44
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;Halides;Pyridines;Pyridine;Variety of halogenated heterocyclic series;Heterocycle-Pyridine series;alkyl bromide| alkyl chloride
• Mol File: 22918-01-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: <30℃
• Boiling Point: 98°C
• Flash Point: >110℃
• Appearance: light yellow liquid
• Density: 1.736 g/cm³
• Vapor Pressure: 0.19mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Room temperature.
• Solubility: soluble in Methanol
• PKA: 0.12±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-4-chloropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-chloropyridine(22918-01-0)
• EPA Substance Registry System: 2-Bromo-4-chloropyridine(22918-01-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-41-37/38-22
• Safety Statements: 26-36/37/39-39
• WGK Germany: 1
• Hazardous Substances Data: 22918-01-0(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow liquid

InChI:InChI=1/C5H3BrClN/c6-5-3-4(7)1-2-8-5/h1-3H

Upstream product

• 5470-22-4 4-chloropicolinic acid 
• 19798-80-2 2-Amino-4-chloropyridine 
• 626-61-9 4-Chloropyridine 

Downstream Products

• 89488-29-9 2-bromo-4-methoxypyridine 
• 1459257-96-5 3-(4-chloropyridin-2-yl)-N-isopropyl-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine 
• 1459258-15-1 3-(4-chloropyridin-2-yl)-1-(4-methoxybenzyl)-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine 
• 1459257-80-7 3-(4-chloropyridin-2-yl)-N-isopropyl-1-trityl-1H-pyrazolo[4,3-c]pyridin-4-amine 
• 1433859-86-9 dibenzyl (2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-4-(1-methyl-5-(5-methylisoxazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methyl phosphate 
• 1433859-79-0 dibenzyl (2-(6-tert-Butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-4-(1-methyl-5-(5-methylisoxazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)methyl phosphite 
• 1433847-78-9 6-tert-butyl-8-fluoro-2-[3-(hydroxymethyl)-4-[1-methyl-5-[(5-methylisoxazol-3-yl)amino]-6-oxo-pyridazin-3-yl]-2-pyridyl]phthalazin-1-one 
• 1289197-78-9 2-bromo-4-chloropyridine-3-carboxaldehyde 
• 1433855-51-6 (2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-4-(1-methyl-5-(5-methylisoxazol-3-ylamino)-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)methyl acetate 
• 1433846-72-0 6-tert-butyl-2-[4-[6-[(1-ethylpyrazol-4-yl)amino]-4-methyl-5-oxo-pyrazin-2-yl]-3-(hydroxymethyl)-2-pyridyl]-8-fluoro-phthalazin-1-one 
• 1433852-40-4 (2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-4-(6-(1-ethyl-1H-pyrazol-4-ylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)pyridin-3-yl)methyl acetate 
• 1433851-36-5 3-(acetoxymethyl)-2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)pyridin-4-ylboronic acid 
• 1070870-42-6 2-bromo-4-chloro-3-(3-ethylphenyl)pyridine 
• 1345971-95-0 C₂HF₃O₂*C₂₆H₂₅ClF₃N₃O₂ 

Relevant articles and documents

Purification method 2 -bromine -4 -chloropyridine

The purification method of 2 -bromo -4 -chloropyridine comprises the following steps: 1) 2 -bromo -4 -chloropyridine crude is added first organic solvent, excess sulfuric acid is added, and filtered to obtain first filtrates after being fully reacted. 2) The first filtrate was washed in second organic solvent, filtered to give second a filtrate. 3) The second filtrate was added third organic solvent, an excess of an aqueous alkaline aqueous solution was added, and the mixture was sufficiently reacted to obtain 2 - bromo -4 -chloro pyridine solution. The method is simple and feasible, and is suitable for industrial production.

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.